| NCT ID | NCT02753777 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Pemphigus Vulgaris |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2016-04 |
| Primary Completion | 2030-01-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2016-04 with a primary completion date of 2030-01-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Eligibility Criteria
Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid * Subjects able to give informed consent Exclusion Criteria: * Patients who are under age 18 years. * Patients without pemphigus or pemphigoid diseases * Penn employees * Penn students * Cognitively impaired persons
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02753777 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pemphigus Vulgaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02753777 currently recruiting?
Yes, NCT02753777 is actively recruiting participants. Contact the research team at werth@pennmedicine.upenn.edu for enrollment information.
Where is the NCT02753777 trial being conducted?
This trial is being conducted at Philadelphia, United States, Philadelphia, United States, Philadelphia, United States.
Who is sponsoring the NCT02753777 clinical trial?
NCT02753777 is sponsored by University of Pennsylvania. The trial plans to enroll 150 participants.